International Journal of Basic and Clinical Studies (IJBCS)
2012;1(1): 20-3! "u#u S Co$%arison of t&e 'roduct (ife C)cle Cost S)ste$ wit& t&e *raditional Cost S)ste$ and its +%%lication on a '&ar$aceutical Co$%an) Serdar ",-, . . Social Sciences /ocational 0i1& Sc&ool2 Researc& +ssistant2 Istan3ul ,niversit) +3stract The developments in information technologies in the world have led to developments in the technologies used in production. Labor-intensive production technology has been replaced by computer-controlled production. Enterprises are carrying out their production and sales activities in a fierce competition environment and as a result of consumers demand of quality and reliable products and quick distribution channels from production enterprises, enterprises have started to concentrate on their products by striving for high quality low cost, automation, fleible production and use of technology and information. The heavy increase in the technological change both in the global pharmaceutical industry and in other sectors has dramatically shortened the life cycles of products and means of production. !oreover, the increasing competition has also shortened the life cycles of products, reduced the prices of products and compelled enterprises to revise new products. Thus the product life cycle cost approach has come into prominence which focuses on the management of the costs and cost- effectiveness throughout the life-cycle that starts with the pre-production of products and services and continues until the disposal of the products and recalling of the products from the market. The aim of this study is to put forth the function and importance of the product life cycle cost method, which has emerged as a method that makes up the deficiencies of the traditional cost accounting, within the scope of cost management and to underline the benefits of the said method for firms, especially with respect to cost saving. The differences between the two methods were discussed by means of the application of the product life cycle cost method on a pharmaceutical firm. Jel Code: 451 "e) 6ords: Life "ycle "osting, #roduct Life "ycle !anagement, #roduct Life "ycle #rocess, $ai%en "osting, Target "osting, #harmaceutical "ompany 20 Review International Journal of Basic and Clinical Studies (IJBCS) 2012;1(1): 20-3! "u#u S Introduction The concept of #roduct Life "ycle "ost &#L""' was first used in in the mid-()*+s as an auiliary means to be used by the ,nited -tates .epartment of .efense in the main defense tenders. /n ()0* a pro1ect entitled 2Life cycle budgeting and costing as an aid in decision making3 was initiated by the ,nited -tates .epartment of 4ealth, Education and 5elfare &('. The adoption of life cycle thinking has been very slow in the other industries &6'. #ublic sector has also been a relevant promoter for life cycle cost calculations &7'. Later on this situation was changed with the adoption of the first chapter of the /-8 (9+9+, a part of the international environmental protection standard. The philosophy of product life cycle includes the following issues &9': Life cycle valuation Life cycle management Life cycle costing Ecodesign. (iterature Review /n literature, about #L"" method, various academic studies has been done by diffrerent branch of sciences. The summary of these studies are given below; .hillon study about twentythree different types of life cycle cost models. -ome of the #L"" models are general and some of them are specific life cycle cost models. The models which are considered as general category are not very general. This is because of some of them consider ma1or cost elements and some of them are based on some assumptions. /n conclusion, some of these models are product specific and the other models are general to some etent. <enerally, these models are imperfect because they dont have a wide life cycle perspective. &=' #L"" method is used to asist on decision making by the >** of the companies in a -wedish building industry -tudy and the some analysis method is used by >9+ of city administrations in a ,.- -tudy to assess their building pro1ects. &*-0' 4wang and ?ae developed a performance model which they use to manufacture manufacturing facility design considering systems configuration, @A! system and the design life cycle cost. The life cycle cost model considers acquisition cost, maintenance cost, breakdown repair cost and logistic support cost. &B' #L"" 21 Review International Journal of Basic and Clinical Studies (IJBCS) 2012;1(1): 20-3! "u#u S !odel has been used only = > of large industrial companies in a Cinnish -tudy by 4yvDnen. &)' -andberg and ?oart performed #L"" model for the conceptual development of the hardware part of functional &total care' products. The discussed design support model can be used to assess life cycle cost and create a view of how decisions between a number of design, performance, and manufacturing and maintenance activities affect each other in conceptual design. &(+' Enparant%a and @evilla studied about a life cycle cost calculation and management system for machine tools. The #L"" model considers acquisition cost, operation cost, maintenance cost and turnoverEscrap cost. &((' "arpentieri and #apariello performed a #L"" calculation model for automotive production line. The model has two supporting databases which are, preventive maintenance and corrective maintenance database. &(6' #L"" calculation is used Aye et al. for analyse a range of property and construction options for a building. &(7' .avis and Fones performed draft to document and analy%e #L"" for documenting and analy%ing #L"" using a simple network based representation. The casual factors that lead to costs and the effect of each technology factor are identifies the and analyses the total cost implications to introduce a technology factor are analysed by the #L""-GET model. &(9' To quantify disposal costs, -tudy of Abraham and .ickinsons the disposal of a building in which #roduct Life "ycle "ost calculation is used. &(=' 5idiyanto and $ato studied about forecasting the cost and performance of coal fired power plant with and without pollution control by #L"" model. &(*' -terner developed a model to uses #L"" methodology to calculate the total energy costs of buildings. &(0' 4a11 and Aouad performed a draft of the #L"" model with ob1ect oriented and H@ technologies for a building which calculates the #L"" at two different levels. &(B' The results of -afety, !aintainability, Availability and @eliability in .esign Iis performed ?aaren and -mit model development phase. Their !odel incorporates reliability, availability, maintainability, supportability and #L"" aspects in the design and development process of large scale comple technical systems. &()' #L"" Analysis of photovoltaic water pumping system is also performed in Coster and 4anleys study. &6+' 22 Review International Journal of Basic and Clinical Studies (IJBCS) 2012;1(1): 20-3! "u#u S Asiedu and <u presented a state of the art review of product life cycle cost analysis models until ())0. The cost estimation models are divided into three groups which are analogous, parametric and detailed. /n conclusion the reviewed models are restricted to simple operations or one phase of life cycle often the design and manufacturing stage. This gives us the necessity about opinion to develop models which include more parts of the product life cycle methods. &6(' An analytic method to estimating reliability and life cycle cost of process safety system is presented by ?odsberg and 4okstad study. &66' 1! 7efinitions of t&e 'roduct (ife C)cle Cost S)ste$ The product life cycle cost is epressed as the total cost that include the planning, design, acquisition and maintenance costs that occur during the entire product life cycle and other costs that are directly related to the product and incurred in order to acquire or use the product &67'. /n other words the product life cycle cost method defines and measures all costs that occur throughout the economic life of physical assets and targets the optimi%ation of the cost of the ownership and acquisition with the present value method &69'. The product life cycle is a process where &6='; the life of the product is limited, different marketing, production and financing functions are needed in each phase of the product life, the product, cost and profit performance of an enterprise are presented as a means of managerial control. 2! '&ases of t&e 'roduct (ife C)cle Cost S)ste$ The product life curve begins with the introduction of the new product to the market. The product 2dies3 if the potential of the product in the market is destroyed due to technological deficiency or improper strategies followed in the environment of uncertainty. The product life curve defines the phases of a new product in the market. These phases are introduction, growth, maturity and abandonment and different product, price, distribution and promotion efforts are deployed in each phase. #roduct planning is the first step to building the life curve system. 23 Review International Journal of Basic and Clinical Studies (IJBCS) 2012;1(1): 20-3! "u#u S As can be seen in the Cigure ( below, introduction phase is the phase where the product meets the target market. /n this phase sales increase is slow and the profit rate is low. The unit costs are high &6*'. Losses are made in this phase since there is a high number of promotion activities and a low sales volume &60'. The growth phase lasts from the break-even point until the maturity period and enterprises want to prolong this phase. -ales increase and profit starts to increase. The number of the competitors in the market also increases. The product enters also other sections of the market and the distribution network widens. /n the maturity phase, the sales and competition are at the highest level. Enterprises strive to protect their market shares. -ince enterprise runs in full capacity, unit costs are at the lowest level. The abandonment phase lasts until the transition to loss due to the decrease in sales. The decrease rate of each product is different. The decrease period may be slow. /t is difficult to recogni%e that the product is in this phase. 5hen sales and profitability decrease, some enterprises abandon the market. The ones that remain in the market, on the other hand, reduce the number of their products. These enterprises eit the small market sections and weak commercial channels and reduce their prices by cutting promotion budgets.
/n line with the developments, especially pharmaceutical companies reduce the sales of their products in the market or even recall the products from the market due to the competitive environment or an invention which is more advanced than their invention. 8i1ure 1! *&e Relations&i% 3etween 'roduct (ife C)cle and 'rofita3ilit) (2)! /ntroduction <rowth Maturity Decline -ales #rofits @eplacement @eplacement *i$e 'rofits9 Sales 24 Review International Journal of Basic and Clinical Studies (IJBCS) 2012;1(1): 20-3! "u#u S The life phases of a pharmaceutical product are demonstrated on a product life cycle curve. As can be seen in Cigure 6 below, this curve shows the situation of the pharmaceutical product to be introduced to the market by taking into consideration the sales volume and profitability factors. 8i1ure 2! *&e Relations&i% 3etween 'roduct (ife C)cle and 'rofita3ilit) /olu$e (2:)! Sales /olu$e
25 Review International Journal of Basic and Clinical Studies (IJBCS) 2012;1(1): 20-3! "u#u S
#lanning #hase #reliminary .esign .etailed .esign #roduct #hase Logistic -upport As can be seen in Cigure 7, according to the life cycle costing approach, an important part of the production and after sales costs are related to decisions made in the design phase. Therefore, the production and usage costs that depend on the pharmaceutical product to be produced are shaped in the design phase, before the production phase. 5hether in case of drugs or in case of products, only 6+> of the costs can be manipulated in the production phase and the following phases and this fact necessitates a cost approach which is not limited to the production phase &7('. Cigure 9 below shows the flowchart of all phases. 8i1ure 5! 'roduct (ife C)cle Cost 'rocess (32)! 3! *&e Conce%t of 'roduct (ife C)cle fro$ t&e /iew%oint of 'roducer The product life cycle cost system process is discussed through three viewpoints: consumer viewpoint, producer viewpoint and marketer viewpoint. /ndeed, these different viewpoints concerning life cycle constitute a whole. The maimi%ation of the return to be obtained from the product life or the minimi%ation of the costs cannot be achieved without understanding the intertangled relationships between these different angles. The producer, calculations consist of the estimation of the costs of design, engineering, industriali%ation and production of a new product and in the analysisof these costs throughout the life cycle &77'. The drug producer has to know what kind of a value is gained by the customer with the product it offers and the cost incurred by the customer in order to gain the said value &79'. Cor instance, the cost of a car Research Development Research Development
Desing
Desing
Product
Product Marketing Marketing Customer Customer High Costs Low Costs 'roduct (ife C)cle 'rocess 26 Review International Journal of Basic and Clinical Studies (IJBCS) 2012;1(1): 20-3! "u#u S from the viewpoint of consumer &acquisition cost J usage cost J maintenance cost' is the sales value of the car. ?oeing "ompany paid special attention to the customer life cycle costs while designing ?oeing 000. /t shortened the time to be spent for routine maintenance by performing it in different areas and reduced the airplanes acquisition and maintenance costs and thus 1ustified the high price of ?oeing 000 &7='. Even though the product life cycle costs of the producer differ depending on the activities performed during the life cycle, they generally include the following phases &7*'; (. The concept of product, 6. .esign, 7. .evelopment, 9. #roduction, =. Logistic -upport. The product life cycle costs of the producer are obtained by adding all costs that occur in the above phases. 5hile the product life cycle cost analysis from the viewpoint of consumer is used as a part of the market analysis conducted to find the answer to the question 2how much should the features of the products cost for the consumer throughout the product life cycleK3, the producer life cycle costing analysis tries to find out the cost effects of the features of the products &70'. /n other words, it eplores the effects of a cost incurred for a feature of the product on the product profitability. Table ( below shows the life cycle cost system that belongs to different sections. *a3le 1! 8or$ation of Costs accordin1 to t&e (ife C)cles of 7ifferent 'roducts (3)! (ife 'roduct *)%es C)cle '&ases 6ar%lanes Co$$ercial +ir%lanes ;uclear 4issiles Co$%uter 'ro1ra$s @esearch-.evelopment and .esign 6(> 6+> 6+> 0=> #roduction 9=> 9+> *+> - -ervice and .isposal 79> 9+> 6+> 6=> Average Life "ycle #eriod 7+ years 6= years 6-6= years = years 5! Co$%arison of t&e 'roduct (ife C)cle Cost S)ste$ wit& t&e *raditional Cost S)ste$ 27 Review International Journal of Basic and Clinical Studies (IJBCS) 2012;1(1): 20-3! "u#u S #roduct life cycle costing is a process used throughout the total life cycle of a product. These costs are eamined in the Cigure below with respect to being charged on the producer and consumer. The traditional product life cycle activities are displayed on the left side of the Cigure. 4owever, the broader definition of life cycle also includes the strengthening activities which are displayed on the right side of the Cigure. Accordingly, the life of the product ends when the product is no longer useful or when the product is worn out. The producer and user costs in the real product life cycle are eamined in the Cigure = below: 8i1ure! < *&e Real (ife C)cle and Costs of t&e 'roduct &7)'. The differences between the life cycle costing and the traditional costing are presented below &9+'. *raditional 4et&od '(CC 4et&od Takes the product development and logistic support costs as period cost. "harges the product development and logistic support costs on the product cost. Takes into consideration only the costs concerning production in product costing. Takes into consideration all costs &including period epenses' that can be related to the product in product costing. Attaches importance to the control of the costs only in the production phase. Attaches importance to cost management from the development phase forward. /s based on periodical reporting. /s based on product life cycle reporting. 28 Review International Journal of Basic and Clinical Studies (IJBCS) 2012;1(1): 20-3! "u#u S <! *&e Relations&i% of t&e 'roduct (ife C)cle Cost 4et&od wit& ot&er Strate1ic Cost 4et&ods <enerally, there are three phases in the life cycle of a product: planning, production and disposal. There are three basic means of decision-making in the said life cycle according to the product costs: #roduct life cycle costing Target costing $ai%en costing 5hile target costing supports the development and design phases of new models, $ai%en costing supports the eisting products in the production phase. Target costing is an approach that is closely related to the design and development of a new product. Another important issue to be considered with respect to target costing is that the bigger part of the cost of a product is determined in the product design phase. Especially, when the fact that pharmaceutical companies incur most of the costs in the @L. phase is taken into consideration, the importance of target costing comes into the picture. There is little to be done after a product is designed and started to be produced. Cor, most of the opportunities for reducing the cost of the product are obtained and used during the design of the product &9('.The target costing method and the product life cycle costing method comply with each other precisely at this point and the two methods are intertangled. The target costing approach determines a target cost and aims at designing the product according to the determined cost and thus to achieve the targeted cost instead of designing a product and finding out the cost of the product &96'. /ndeed, the target costing has emerged out of the need to attain early cost information which is required to be deduced, in the earliest possible phases &planning and design' of a products life cycle, from the market structure and the strategies of the enterprise in order to reali%e the planning, management and control aims &97'. 8i1ure =! 8or$ation of t&e 'roduct (ife C)cle Costs In Case *ar1et Costin1 and *raditional 4et&ods are ,tili#ed (55)! Cost Target "ost and #L""
29 Review International Journal of Basic and Clinical Studies (IJBCS) 2012;1(1): 20-3! "u#u S Traditional !ethod and #L""
*i$e Source: Ahmet Hehdi "an, Target "osting, Theory and #ractice3, -akarya #ublishing 4ouse, -akarya, 6++9, p.(09
Enterprises should apply target costing and product life cycle costing in an integrated way. Cor, target costing is meaningful within the approach of product life cycle costing. As can be understood also from the Cigure above, in case the traditional method is used, the product life cycle costs acceleratingly increase in the later phases of the life cycle, slow down in the middle of the life cycle and acceleratingly decrease in the last phase of the life cycle. 4owever, when target costing is used, while relatively more costs are incurred in the early phases of the product life cycle, great cost saving are provided in the later phases of the life cycle . Every ( Euro deducted before the production phase provides B-(+ Euros of saving in the phases following the production phase . As an eample of the firms which utili%e these savings, Toyota has incurred greater costs in the concept determination and design phases of the product and obtained considerable savings in costs in the later phases of changes and additions &9='. The 2more with less3 approach, which was developed by <eneral Electric due to the parts deficiency during the 5orld 5ar //, has afterwards been transformed into an organi%ed effort to investigate the ways of providing the needed functions in a product with minimum cost &9*'. American companies such as Cord and <eneral !otors have also incurred greater costs in the product design phase and gained considerable cost advantage &90'. @olls- @oyce states that B+> of the production costs of 6.+++ parts occurs in the design phase &9B'. $ai%en is a human-based, short-pitch, product-oriented effort that shares information and acts in line with the motto 2the best is the enemy of good3. -ince $ai%en is a philosophy which aims to develop all factors concerning the processes where inputs turn into outputs, $ai%en costing is the use of $ai%en techniques in order to reduce the costs of parts and products at a pre-determined rate. $ai%en costing aims at small but continuous improvements in all 30 Review International Journal of Basic and Clinical Studies (IJBCS) 2012;1(1): 20-3! "u#u S activities of competition-based enterprises by focusing on preventing wastes and reducing costs &9)'. =! +%%lication in '&ar$aceutical Co$%an) "ost management through the product life cycle is applied to a <erman pharmaceutical firm which is called as M. Cirm plans to produce a new pharmaceutical product in 6+(6. #roduct life cycle is accepted as five years. .uring application period, inflation rate is assumed to be constant at 7 >. /n a pharmaceutical firm, items which are included to the application would be affected differently by the inflation rates. -o in this study, inflation rate is taken as 7> in average for all these items included in the application. 5hile estimating items net present value, discount rate is accepted as (6> which is calculated by the weighted average cost of capital. Cor the reliability of the study, dependable data are included to the application and cash flow L cash outflow is accepted as ordinary. /tems those would be a part of cost element in production of the pharmaceutical product &drug' is taken into account. Estimated data of produce and sale amounts from 6+(6 to 6+(*, are included to the application. These data are 1ust e-ante. Cied !oney Approach is used as a base in this study. /n this study, along the application of cost management through the product life cycle, firstly items that would be a part of cost element in production would be increased by the inflation rate. Then items which were increased by the inflation rate would be discounted by the net present value. At the last stage, unit cost, sale price, and cost amount through the life cycle of 31 Review International Journal of Basic and Clinical Studies (IJBCS) 2012;1(1): 20-3! "u#u S the product would be calculated and afterwards the statement of income would be drawn according to the cost management of product life cycle. *a3le 2 : >sti$ated Cost 7ata of ;ew 7ru1 'roduction in 2012 C?S*S (@) T8TAL 1!'re %roduction Costs #roduct #lanning and .esign "oncept "osts 0++.+++ #roduct .esign and .evelopment "osts 9++.+++ @esearch and .evelopment "osts (++.+++ T8TAL 1!200!000 2!'roduction Costs 2!000!000 3!+fter Sales Costs #harmacists- .rug 8ffices "osts of .istribution B+.+++ !arketing "osts 7++.+++ 5arranty "osts =+.+++ Advertisement- #resentation "osts 0+.+++ T8TAL <00!000 32 Review International Journal of Basic and Clinical Studies (IJBCS) 2012;1(1): 20-3! "u#u S *a3le 3 >n&ance$ent of 'redicted Costs2 of *&e ;ew 'roduct +ccordin1 to *&e Inflation Coefficient Rate and 7iscount to *&e Base Aear
Costs 2012 Inflation +dBust$ent Coefficient Costs @ 7iscount 8actor C12 *?*+( ' r e - ' r o d u c t i o n C o s t s #roduct #lanning and .esign "oncept "osts 0++.+++(,+7 06(.+++ +,B)6) *97.0B( #roduct .esign and .evelopment "osts 9++.+++(,+7 9(6.+++ +,B)6) 7*0.B0= @esearch and .evelopment "osts (++.+++(,+7 (+7.+++ +,B)6) )(.)*) *a3le 5! >n&ance$ent of 'redicted Costs2 of *&e ;ew 'roduct +ccordin1 to *&e Inflation Coefficient Rate in *&e +%%lication 'eriod! Cost9Aears 2012 2013 2015 201< 201= ' r o d u c t i o n
C o s t s"ost ?efore /nflation "oefficient Application 6.+++.+++ Inflation Coefficient (,+7 (,+* (,+) (,(6 (,(= "ost After /nflation "oefficient Application 6.+*+.+++ 6.(6+.+++ 6.(B+.+++ 6.69+.+++ 6.7++.+++ ' & a r $ a c i s t s -
7 r u 1 ? f f i c e s D
C o s t s
o f 7 i s t r i 3 u t i o n "ost ?efore /nflation "oefficient Application B+.+++ Inflation Coefficient (,+7 (,+* (,+) (,(6 (,(= "ost After /nflation "oefficient Application B6.9++ B9.B++ B0.6++ B).*++ )6.+++ 4 a r E e t i n 1
C o s t s "ost ?efore /nflation "oefficient Application 7++.+++ Inflation Coefficient (,+7 (,+* (,+) (,(6 (,(= "ost After /nflation "oefficient Application 7+).+++ 7(B.+++ 760.+++ 77*.+++ 79=.+++ 6 a r r a n t ) C o s t s "ost ?efore /nflation "oefficient Application =+.+++ Inflation Coefficient (,+7 (,+* (,+) (,(6 (,(= 33 Review International Journal of Basic and Clinical Studies (IJBCS) 2012;1(1): 20-3! "u#u S "ost After /nflation "oefficient Application =(.=++ =7.+++ =9.=++ =*.+++ =0.=++ + d v e r t i s e $ e n t - ' r e s e n t a t i o n
C o s t s "ost ?efore /nflation "oefficient Application 0+.+++ Inflation Coefficient (,+7 (,+* (,+) (,(6 (,(= "ost After /nflation "oefficient Application 06.(++ 09.6++ 0*.7++ 0B.9++ B+.=++ *a3le <! >n&anced 'redicted Costs 3) t&e Inflation Coefficient Rate in t&e +%%lication 'eriod 7iscountin1 in t&e Base Aear!
Costs +fter Inflation Coefficient +%%lication @ 7iscount 8actor C12 Inflation Coefficient +%%lied >sti$ated Costs (2012 Base Aear) ' r o d u c t i o n C o s t s 6.+*+.+++ +,B)6) (.B7).709 6.(6+.+++ +,0)06 (.*)+.+*9 6.(B+.+++ +,0((B (.==(.069 6.69+.+++ +,*7== (.967.=6+ 6.7++.+++ +,=*09 (.7+=.+6+ ' & a r $ a c i s t s -
7 r u 1 ? f f i c e s D
C o s t s
o f 7 i s t r i 3 u t i o n B6.9++ +,B)6) 07.=0= B9.B++ +,0)06 *0.*+7 B0.6++ +,0((B *6.+*) B).*++ +,*7== =*.)9( )6.+++ +,=*09 =6.6+( 4 a r E e t i n 1 7+).+++ +,B)6) 60=.)+* 7(B.+++ +,0)06 6=7.=(+ 760.+++ +,0((B 676.0=) 34 Review International Journal of Basic and Clinical Studies (IJBCS) 2012;1(1): 20-3! "u#u S C o s t s 77*.+++ +,*7== 6(7.=6B 79=.+++ +,=*09 ()=.0=7 6 a r r a n t ) C o s t s =(.=++ +,B)6) 9=.)B9 =7.+++ +,0)06 96.6=6 =9.=++ +,0((B 7B.0)7 =*.+++ +,*7== 7=.=BB =0.=++ +,=*09 76.*6* + d v e r t i s e $ e n t - ' r e s e n t a t i o n
C o s t s 06.(++ +,B)6) *9.70B 09.6++ +,0)06 =).(=6 0*.7++ +,0((B =9.7(+ 0B.9++ +,*7== 9).B67 B+.=++ +,=*09 9=.*0* *a3le =! Cost of *&e ;ew 'roduct (ife C)cle *&rou1& *&e Aears! Cost9Aear 2012 2013 2015 201< 201= *?*+( #roduct #lanning and .esign "oncept "osts *97.0B( *97.0B( #roduct .esign and .evelopment "osts 7*0.B0= 7*0.B0= @esearch and .evelopment "osts )(.)*) )(.)*) #roduction "osts (.B7).70 9 (.*)+.+* 9 (.==(.06 9 (.967.=6 + (.7+=.+6 + 0.B+).0+ 6 #harmacists- .rug 8ffices .istribution costs 07.=0= *0.*+7 *6.+*) =*.)9( =6.6+( 7(6.7BB !arketing "osts 60=.)+* 6=7.=(+ 676.0=) 6(7.=6B ()=.0=7 (.(0(.9= = 5arranty "osts 9=.)B9 96.6=6 7B.0)7 7=.=BB 76.*6* ()=.697 Advertisement- #resentation "osts *9.70B =).(=6 =9.7(+ 9).B67 9=.*0* 607.79+ *?*+( 7.9+6.B9 6 6.((6.=B + (.)7).*= = (.00).9+ + (.*7(.60 = ).0*6.(6 B 35 Review International Journal of Basic and Clinical Studies (IJBCS) 2012;1(1): 20-3! "u#u S *a3le F! Calculation of ,nit Costs 3) ,sin1 Bot& t&e *raditional Cost S)ste$ and *&e Cost ?f *&e ;ew 'roduct (ife C)cle S)ste$ Cost9Aears 2012 2013 2015 201< 201= 6 i t &
* & e
+ % % l i c a t i o n
' r o d u c t
( i f e C ) c l e
C o s t
4 e t & o d
#roduct Life "ycle "ost 7.9+6.B96 6.((6.=B+ (.)7).*== (.00).9++ (.*7(.60= Corecast #roduction 8utput (++.+++ (6+.+++ (9+.+++ (*+.+++ (0+.+++ #roduct Life "ycle ,nit "ost 79,+7 (0,* (7,B= ((,(6 ),* 6 i t &
* & e
+ % % l i c a t i o n * r a d i t i o n a l
C o s t
4 e t & o d #roduction "ost (.B7).709 (.*)+.+*9 (.==(.069 (.967.=6+ (.7+=.+6+ Corecast #roduction 8utput (++.+++ (6+.+++ (9+.+++ (*+.+++ (0+.+++ #roduct ,nit "ost (B,7) (9,+B ((,+B B,) 0,*B *a3le ! >n&ance$ent of t&e 'redicted Sales Revenue of *&e ;ew 'roduct +ccordin1 to *&e Inflation Coefficient Rate and 7iscount to t&e Base Aear! Sales Revenue 9Aears 2012 2013 2015 201< 201= *?*+( B e f o r e
I n f l a t i o n C o e f f i c i e n t + % % l i e d
> s t i $ a t e d S a l e s
R e v e n u e =.+++.+++ 36 Review International Journal of Basic and Clinical Studies (IJBCS) 2012;1(1): 20-3! "u#u S I n f l a t i o n C o e f f i c i e n t (,+7 (,+* (,+) (,(6 (,(= + f t e r
I n f l a t i o n C o e f f i c i e n t
+ % % l i e d > s t i $ a t e d
S a l e s R e v e n u e =.(=+.+++ =.7++.+++ =.9=+.+++ =.*++.+++ =.0=+.+++ 7 i s c o u n t 8 a c t o r
C 1 2 +,B)6) +,0)06 +,0((B +,*7== +,=*09 I n f l a t i o n
C o e f f i c i e n t
a n d
7 i s c o u n t + % % l i e d
S a l e s
R e v e n u e
( 2 0 1 2
B a s e
A e a r ) 9.=)B.97= 9.66=.(*+ 7.B0).7(+ 7.==B.B++ 7.6*6.==+ ().=69.6== G '0+R4+C>,*IC+( 4+;,8+C*,RI;H B,SI;>SS I;C! I;C?4> S*+*>4>;* ,;7>R 'R>S>;* /+(,>S ?8 +CC?,;* B>*6>>; 2012-201= Sales 1:!<25!2<< 'roduction Costs !:13!32= -'roduction Cost 0.B+).0+6 -'re%roduction Cost (.(+7.*69 Hross 4ar1in 10!=10!:2: 37 Review International Journal of Basic and Clinical Studies (IJBCS) 2012;1(1): 20-3! "u#u S +fter Sales Costs 1!:<2!52= -'&ar$acists- 7ru1 ?ffices 7(6.7BB 7istri3ution Costs -4arEetin1 Costs (.(0(.9== -6arrant) Costs ()=.697 -+dvertise$ent- 'resentation Costs 607.79+
;et 'rofit !=<!<03
'rofita3ilit) Ratio 99> *a3le :! 7istri3ution of t&e Costs 6&ic& are ?ccured in t&e *otal 'roduct (ife C)cle 'eriod 7R,H 'R?7,C* (I8> CAC(> *?*+( C?S* C?S*S +4?,;* *&e S&are of *otal C 're%roduction Cost (.(+7.*69 (+ 'roduction Cost 0.B+).0+6 06 +fter Sales Costs (.)=6.96* (B 'roduct (ife C)cle *otal Cost (+.B*=.0=6 (++ *&e results of t&is a%%lication can 3e su$$ari#ed as follows ; As it can be seen from the table, cost structure of the pharmaceutical firm M all through the product life cycle of the new product, is like that ; > 06 of total cost is production cost and > 6B of total cost is composed of before production and after sale costs. /f it were analy%ed by the Traditional "ost -ystem, only the cost of production would have been focused. /n that case, before production and after sale costs were going to be ignored and cost reduction would be 1ust counted in the production cost. /n conclusion, cost of product life cycle gives dependable results rather than the traditional cost system. The other important conclusion can be drawn from this study is that unit cost. ,nit cost which is calculated by the Traditional "ost -ystem means the unit production cost. /f a 38 Review International Journal of Basic and Clinical Studies (IJBCS) 2012;1(1): 20-3! "u#u S pharmaceutical firm ignored the other cost units which would be occurred through the product life cycle period then the financial statements of the firm wouldnt reflect the realities. The new technological developments lower the production costs but raises the non-production costs. @ecent studies elucidate that > )+ of the total costs of product consists of pre- production and after production costs. ?y analy%ing the Get #resent Halue of the #ro1ect which is greater than %ero, it can be said that this pro1ect is reali%able one. #roducts real added value for the firm can be drawn from the income statement which inludes all the costs of the product through its life cycle. ?y income statement, a pharmaceutical firm can reali%e if the product bears the costs or not. As the income statement is made up within the frame of net present value, relevant items present values are analy%ed as the sum of their present values form 6+(6 to 6+(*.
/n fact, income statements which are drawn by periods in traditional accounting system does not indicate the real added value of the product to the firm. #eriodical income statements reflect 1ust the relevant periods income and ependiture and this causes the handicap of evaluation all income and ependiture of the product all through its life cycle as a whole. /n that point, to attain the profitability ratio that the firm request, the question of which cost components should be saved, plays an important role in the analy%e. Conclusion /ncreasing competition and globali%ation force the firms to take notice of their rivals. /n these competitive environment, firms should take notice of not only their production cost and but also pre-production and after production costs. Gowadays, policy of production has been changed and customer oriented production has become prominent. "ustomers play an important role in the production period of the firms. /n conclusion, policy of the cost oriented sales has been changed. Gowadays, in this increasing competitive environment, the viewpoint of the production technologies changes day by day within the development of information technology. Eecutives of the #harmaceutical firms are obliged to focus on all the production costs instead of significant 39 Review International Journal of Basic and Clinical Studies (IJBCS) 2012;1(1): 20-3! "u#u S part of the production process according to cost of the product life cycle period. 5ithin the frame of #roduct Life "ycle "ost -ystem, not only the cost of production but also the other costs of non-production process. ?y this means, #harmaceutical firms can obtain savings from the costs in the production process. References (. Langdon, .avis. Literature review of Life "ycle "osting and Life "ycle Assesmant. .raft @eview Fune 6++*:* 6. Lindholm, A. and -uomala, #. Learning by "osting: -harpening "ost /mage through Life "ycle "ostingK .The 0th !anufacturing Accounting @esearch "onference. Tampere, Cinland, !ay 7+ - Fune (, 6++= 7. 5oodward, .. Life "ycle "osting N Theory, Information Acquisition And Application. /nternational Fournal of #ro1ect !anagement, ())0; (=:&*':77=-799 9. #etr Gemeck ve Alena $ocmanova. /ntegration of Life "ycle As A ?usiness Aproach. Economics and !anagement, 6++0:=6= =. ?. -. .hillon. Life "ycle "osting: Techniques, !odels and Applications. <ordon and ?reach -cience #ublishers,()B): 9*-0) *. -terner, E. Life-"ycle "osting And /ts ,se In The -wedish ?uilding -ector. ?uilding @esearch L /nformation, 6+++;6B:&=':7B0-7)7 0. Ardit, .. and !essiha 4.!. Life "ycle "ost Analysis &L""A' in !unicipal 8rgani%ations. Fournal of /nfrastructure -ystems, ()));=:&(':(-(+ B. 4avang et al; 4. 4wang, -. ?ae and <. "ho. #erformance !odel for !anufacturing Cacility #lanning based on -ystem "onfiguration, @A! and L"". /nternational Fournal of /nnovative "omputing, /nformation and "ontrol, /"/" /nternational, Cebruary 6++0;7:&(':())-6+) ). 4yvDnen, T. !anagement accounting and information systems: E@# versus ?o?. European Accounting @eview, 6++7;(6:&(':(==-(07 (+. !. -andberg, #. ?oart and T. Larsson. Cunctional #roduct Life-cycle -imulation !odel for "ost Estimation in "onceptual .esign of Fet Engine "omponents. "oncurrent Engineering: @esearch and Applications, .ec 6++=;(7:&9':77(-796 ((. @. Enparant%a, 8. @evilla, A. A%karate and F. Oendoia. A Life "ycle "ost "alculation and !anagement -ystem for !achine Tools. (7th "@/# /nternational "onference on Life "ycle Engineering, 6++*:0((-0(* 40 Review International Journal of Basic and Clinical Studies (IJBCS) 2012;1(1): 20-3! "u#u S (6. !. "arpentieri and !. #apariello. A Life "ycle "ost Cramework for Automotive #roduction Lines. (7th "@/# /nternational "onference on Life "ycle Engineering, 6++*:0(0-066 (7. Aye L, ?amford G, "harters ?, @obinson F. Environmentally sustainable development: a life-cycle costing approach for a commercial o$ce building in !elbourne, Australia. "onstruction !anagement and Economics, 6+++;(B: )60-79 (9. G. .avis, F. Fones and L. 5arrington. A Cramework for .ocumenting and Analy%ing Life "ycle "osts using a -imple Getwork ?ased @epresentation. , #roceedings of Annual @eliability and !aintainability -ymposium, /EEE, 6++7:676-67* (=. Abraham .!, .ickinson @F. .isposal costs for environmentally regulated facilities: L"" approach. Fournal of "onstruction Engineering and !anagement; ())B; (69: &6':(9*N=9 (*. A. 5idiyanto, -. $ato and G. !aruyama. A L"AEL"" 8ptimi%ed -election of #ower #lant -ystem with Additional Cacilities 8ptions. Fournal of Energy @esources Technology, .ec. 6++6;(69:6)+-6)B (0. -terner E. <reen procurement of buildings: estimation of life-cycle cost and environmental impact. #h. .. dissertation thesis, .epartment of !ining Engineering, LuleMa ,niversity of Technology, 6++6. (B. A. AL-4a11 and <. Aouad. The .evelopment of an /ntegrated Life "ycle "osting !odel using 8b1ect 8riented and H@ Technologies. "onstruction /nformatics .igital Library, ())):0B-()))-6)+( (). @. F. van ?aaren and $. -mit. .esign for @!-EL"" - the .evelopment of a .esign !odel. #roceedings of Annual @eliability and !aintainability -ymposium, /EEE, ())): 77+-77= 6+. @. Coster and ". 4anley. Life "ycle "ost Analysis for #hotovoltaic 5ater #umping -ystems in !eico. 6nd 5orld "onference on #hotovoltaic -olar Energy "onversion, Hienna, Austria, Fuly ())B. 6(. Asiedu P. #roduct Life "ycle "ost Analysis: -tate of the art review. /nternational Fournal of #roduction @esearch, April ())B;7*:&9':BB7-)+B 66. L. ?odsberg and #. 4okstad. A -ystem Approach to @eliability and Life "ycle "ost of #rocess -afety -ystems. /EEE Transactions on @eliability, Fune ())=;99:&6':(0)-(B* 67. -ten, ?engt. Environmental "osts and ?enefits in Life "ycle "osting. !anagement of Environmental Quality, 6++=;(*:&6':(+B 41 Review International Journal of Basic and Clinical Studies (IJBCS) 2012;1(1): 20-3! "u#u S 69. 5oodward, .avid <. Life "ycle "osting-Theory. Information Acquasition and Application. International Fournal of #ro1ect !anagement, ())B;(=:&*':77B 6=. Relik !uhsin. Approaches to #roduct Life "ycle "oost Evaluation 8f Environmental /mpact ?usiness .ecisions. Fournal 8f Accounting and Auditing 8verview, April 6++*:(7+ 6*. ?alyeme%,Cigen Evrim Ilden .eveli, ..Oeynep ?aya%St TahinoUlu. H. Gational !anufacturing @esearch -ymposium. Istanbul "ommerce ,niversity, Govember 6++=:6=-60 60. Erden, -elman. A. "ost !angement and "osting for <lobal "ompetitiveness. Fournal of 5orld of Accounting -cience, .ecember 6++7;=:&9':B0 6B. -evim, Adnan. A "ontemporary !eans in the -trategic #rofit !anagement: #roduct Life "ycle "ost -ystem. Fournal of 5orld of Accounting -cience, 6++6;9:&(':(9+ 6). $arcSoUlu @eVat. -trategic "ost !anagement, Gew Approaches in "ost and !anagement Accounting. Aktif #ublishing 4ouse, Er%urum,6+++:)+ 7+. Altunay, !.Akif. A "ontemporary "osting -ystem: Activity ?ased "osting -ystem and an Application on a Tetile Enterprise. -Wleyman .emirel ,niversity, /nstitute of -ocial -ciences, .epartment of ?usiness !anagement !A Thesis, 6++0. 7(. Altunay, !.Akif. A "ontemporary "osting -ystem: Activity ?ased "osting -ystem and an Application on a Tetile Enterprise. -Wleyman .emirel ,niversity, /nstitute of -ocial -ciences, .epartment of ?usiness !anagement !A Thesis, 6++0. 76. Edward F.?locher, $ung 4."hen, Thomas 5.Lin !c <raw, 4ill. "ost !anagement A -trategic Emphasis. 6nd edition, 6+++:(*B-(*) 77. Asiedu P, <u #. #roduct life cycle cost analysis: state of the art review. /nternational Fournal of #roduct @esearch, ())B;7*:&9':B7*-)+B 79. ?asSk, 8rhan. C; TWrker, Ipek. -trategic "ost Analysis and !anagement. H. Gational !anufacturing @esearch -ymposium, Istanbul "ommerce ,niversity, Govember 6++= 7=. "harles T.4ongren, -rikant !..atar, <eorge Coster, et al. "ost Accounting. #earson /nternational Edition,(7. Edition, !ar 9, 6++B:90( 7*. -usman, /,<erald. #roduct Life "ycle !anagement. #ractices in "ost !anagement ?oston, ())+:66* 70. 5ayne F.!orse, Fames @..avis, Al. L.4artgraves. !anagemen Accounting. AddSsion-5esley #ublushing "ompany, Third Edition, ())(: 77 7B. "an, Hehdi. A. Target "osting, Theory and #ractice. -akarya #ublishing 4ouse, -akarya, 6++9:(0+ 42 Review International Journal of Basic and Clinical Studies (IJBCS) 2012;1(1): 20-3! "u#u S 7). $Dse TunX. .ecision-!aking !eans According to #roduct "osts: #roduct Life "ycle "osting, Target "osting and $ai%en "osting. 8smanga%i ,niversity Fournal of -ocial -ciences, .ecember6++6;7:&6':B9 9+. Retinkaya, Oeynep. -trategic "ost !anagement. $ahramanmaraV -WtXW Imam ,niversity /nstitute of -ocial -ciences, .epartment of ?usiness !anagement !A Thesis, 6++B: 9* 9(. Erden, -elman. A. @elation of "ost !anagement -ystems #roduction Environments and -trategic "ost !anagement. TWrkmen #ublishing 4ouse, 6++6:6+7 96. Erden, -elman. A. @elation of "ost !anagement -ystems #roduction Environments and -trategic "ost !anagement. TWrkmen #ublishing 4ouse, 6++6:6+7 97. "an, Hehdi. A. Target "osting, Theory and #ractice. -akarya #ublishing 4ouse, -akarya, 6++9:(0+ 99. "an, Hehdi. A. Target "osting, Theory and #ractice. -akarya #ublishing 4ouse, -akarya, 6++9:(09 9=. .oUan, Oeki. A Gew Approach to "ost !anagement: Life "ycle "osting !ethod. Fournal of 5orld of Accounting -cience, 6+++;9:)B 9*. Erden, -elman. A. "ost !angement and "osting for <lobal "ompetitiveness. Fournal of 5orld of Accounting -cience, .ecember 6++7;=:&9':BB 90. .oUan, Oeki. A Gew Approach to "ost !anagement: Life "ycle "osting !ethod. Fournal of 5orld of Accounting -cience, 6+++;9:)B 9B. .oUan, Oeki; 4atipoUlu AyVegWl. A -tudy on the Applicability of Target "osting !ethod. Fournal of 5orld of Accounting and Cinance, ())B:6(:(+6 9). Acar, .urmuV; Alkan, 4asan. $ai%en "osting @educing The "ost 8f #roduction. Fournal of 5orld of Accounting -cience, 6++7;=:66 43